1638211-20-7

Basic information

• Product Name: 2-{(1S,4S)-5-[(2R)-3-(2-methoxyphenoxy)-2-hydroxypropyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl}-N-(2,6-dimethylphenyl)acetamide
• CAS NO: 1638211-20-7
• Molecular Weight: 439.555
• Mol File: 1638211-20-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-{(1S,4S)-5-[(2R)-3-(2-methoxyphenoxy)-2-hydroxypropyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl}-N-(2,6-dimethylphenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-{(1S,4S)-5-[(2R)-3-(2-methoxyphenoxy)-2-hydroxypropyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl}-N-(2,6-dimethylphenyl)acetamide(1638211-20-7)
• EPA Substance Registry System: 2-{(1S,4S)-5-[(2R)-3-(2-methoxyphenoxy)-2-hydroxypropyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl}-N-(2,6-dimethylphenyl)acetamide(1638211-20-7)

Safety Data

• Hazardous Substances Data: 1638211-20-7(Hazardous Substances Data)

Upstream product

• 2210-74-4 (R)-1,2-epoxy-3-(2-methoxyphenyloxy)-propane 
• 87-62-7 2,6-dimethylaniline 
• 32433-61-7 2-bromo-N-(2,6-dimethyl-phenyl)-acetamide 
• 848441-96-3 2-[5-benzyl-(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-N-(2,6-dimethylphenyl)acetamide 

Relevant articles and documents

Synthesis of ranolazine derivatives containing the (1S,4S)-2,5- diazabicyclo[2.2.1]heptane moiety and their evaluation as vasodilating agents

Two diazabicyclic analogues of ranolazine, (S,S,S)-5 and (S,S,R)-5, and their epimeric mixture were synthesized. Furthermore, their vasomotor effects on rat aorta rings precontracted with phenylephrine were analyzed. These compounds showed vasodilating effects significantly greater than ranolazine. The vasodilating activities of these analogues have two components, one that depends on the endothelium, due to the release of NO, and another one due to a direct effect on the vascular smooth muscle. The compounds [(S,S,S)(S,S,R)]-5 and (S,S,R)-5 induce, in a manner similar to ranolazine, the release of a prostanoid from the cyclooxygenase pathway, whose vasoconstrictor effect is masked by the predominant vasodilation induced by these compounds. Two diazabicyclic analogues of ranolazine, (S,S,S)-5 and (S,S,R)-5, and their epimeric mixture showed a vasodilating effect significantly greater than ranolazine. This vasodilating activity has two components, one of them endothelium dependent, due to the release of NO, and the other one due to a direct effect on the vascular smooth muscle. In a manner similar to ranolazine, [(S,S,S)(S,S,R)]-5 and (S,S,R)-5 induce the release of a prostanoid, whose vasoconstrictor effect is masked by the predominant vasodilation induced by these compounds.